Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

SWITCHED ONcology. Healthcare Professional Experience Focus Group. www.switchedoncology.com

On 16th April we met with a group of leading healthcare professionals and technology experts to learn more about how the new wave of cancer treatments are affecting everyday practice...

Havas Lynx

- PMLiVE

Avenir acquires Cherry, EY wins new account and GK unites businesses

The latest in healthcare comms

Lucid attend the Wycombe BIG SLEEPOUT in aid of Wycombe Homeless Connection

The inside story from the Big Sleepout on Saturday, 24 November in support of Lucid's charity partner the Wycombe Homeless Connection.

Lucid Group Communications Limited

- PMLiVE

Medical devices probe uncovers need for “drastic regulatory changes”

Report uncovers lax European regulatory system for medical devices

- PMLiVE

Vertex rises on data for cystic fibrosis triple therapy

Company will wait for further results before filing

- PMLiVE

Roche enters NASH race with deal to buy Jecure

Company joins Novartis, Pfizer and others in nascent market

Lucid affirms their commitment to staff development with new central services and HR hires

Lucid has recently appointed two new senior hires to their HR and central services team. Albert Capes joins as the Head of Facilities, bringing with him 11 years’ management experience...

Lucid Group Communications Limited

Bayer symbol

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

A first for Loxo, and a second mutation-based targeted drug

- PMLiVE

NHS says Humira biosimilar deal will save £300m

AbbVie also submitted a bid into tender process

- PMLiVE

Zafgen shares tumble after FDA places hold on diabetes trial

Regulator concerns based on deaths with previous drug

- PMLiVE

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Partners tap into expanding market - but have multinationals to compete with

- PMLiVE

Novartis gets EU nod for Luxturna gene therapy

Approval comes almost a year after it was secured a green light in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links